1785. Regional variation of antimicrobial use in Japan from 2013 to 2016
Session: Poster Abstract Session: Antimicrobial Stewardship: Global Perspectives
Saturday, October 6, 2018
Room: S Poster Hall
  • 20180918_ID week poster_KUSAMA_Ver.3.pdf (1.0 MB)
  • Background:

    Since antimicrobial resistance (AMR) is a global threat, judicious antimicrobial usage is required. Compared to European countries, antimicrobial use (AMU) is relatively low in Japan; however, the use of oral broad-spectrum antimicrobials is relatively high. Although the Japanese national action plan on AMR targets a 50% reduction in use of these oral broad-spectrum antimicrobials by 2020 from the level in 2013, regional variation in AMU in Japan is not well known.


    National antimicrobial sales data from 2013 to 2016 was obtained from IQVIA Japan (Tokyo, Japan), which captures 99% of total sales in Japan. Antimicrobials were classified by the World Health Organization (WHO) defined Anatomical Therapeutic Chemicals (ATC) Classification. WHO measures the number of antimicrobial use by Defined Daily Dose per 1,000 inhabitant-days (DID). From 2013 to 2016, the difference in DID amongst each prefecture was analyzed, and comparison amongst the 3 major regions of East, Central, and West Japan was performed using Mann-Whitney U test.


    From 2013 to 2016, the median (max, min) AMU (DID) change was -0.4 (2.8, -1.6). During the study period, 34 prefectures showed increasing trends, and 13 prefectures showed decreasing trends. Median (max, min) AMU (DID) for total antimicrobials, oral cephalosporins, macrolides, and quinolones in 2016 was 14.4 (18.7, 11.2), 3.5 (6.9, 2.5), 4.5 (6.3, 3.2), and 2.8 (3.7, 1.9), respectively. The median total AMU (DID) in East, Central, and West Japan in 2016 was 13.2, 14.4 and 15.8, respectively. Median oral cephalosporins AMU (DID) in Central Japan (3.69) was significantly higher than that in East Japan (3.33) (p = 0.025). Median oral macrolides AMU (DID) in East Japan (4.11) was significantly smaller than that in Central (4.61) and West Japan (4.70) (p < 0.01). Median oral quinolones AMU (DID) in West Japan (3.28) was significantly higher than that in East (2.29) and Central Japan (2.73) (p < 0.01) (Figure).


    From 2013 to 2016, significant regional variations of oral AMU were observed in Japan. Further studies are needed to specify the appropriate targets of antimicrobial stewardship intervention to reduce oral broad-spectrum AMU in Japan.

    Yoshiki Kusama, MD, Masahiro Ishikane, MD, PhD, Chika Tanaka, RPh, Yuki Kimura, RPh, MPH, Erina Yumura, ME, Kayoko Hayakawa, MD, PhD and Norio Ohmagari, MD, MSc, PhD, AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan


    Y. Kusama, None

    M. Ishikane, None

    C. Tanaka, None

    Y. Kimura, None

    E. Yumura, None

    K. Hayakawa, None

    N. Ohmagari, None

    << Previous Abstract | Next Abstract

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.